SNN Stock Overview
Develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Smith & Nephew plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£25.04 |
| 52 Week High | UK£31.72 |
| 52 Week Low | UK£23.65 |
| Beta | 0.70 |
| 11 Month Change | -14.95% |
| 3 Month Change | -18.91% |
| 1 Year Change | -2.49% |
| 33 Year Change | -26.20% |
| 5 Year Change | -44.83% |
| Change since IPO | 203.51% |
Recent News & Updates
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Nov 10Smith & Nephew Delivering On Its Turnaround Promise
Aug 22Recent updates
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Nov 10Smith & Nephew Delivering On Its Turnaround Promise
Aug 22Smith & Nephew: Work To Be Done But Still Long-Term Potential
Jun 12Smith & Nephew: Orthopedics Growth Continues To Drive Sales Forward
Dec 28Smith & Nephew Getting More Interesting As A Contrarian Idea
Oct 12Smith & Nephew: Entering New Markets But Growth Is Slow Still
Aug 01Smith & Nephew reports FY earnings; initiates FY23 guidance
Feb 21Smith & Nephew: Potential Only Has Value If You Can Execute
Dec 14Smith & Nephew: Still A Buy Despite Short-Term Challenges
Sep 26Smith & Nephew 1H 2022 Earnings Preview
Jul 27Smith+Nephew launches app Wound Compass to help reduce variation in wound care
Jul 12Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier
Jun 01Smith & Nephew: Valuation Looking More Attractive
Jan 26Smith & Nephew Is A Premium Brand That Should Deliver Something Special
Nov 06Smith & Nephew Leveraged To Post-Pandemic Normalization And Self-Help
Sep 02Smith & Nephew plc: Improving Performance Reflected In Price
Jun 18Smith & Nephew: Pandemic Long Tail Reduces Attractiveness
Jan 14Smith & Nephew: A Long-Term Buy And Hold In Medical Devices
Nov 09Shareholder Returns
| SNN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.6% | 1.7% | 0.3% |
| 1Y | -2.5% | 21.4% | 31.1% |
Return vs Industry: SNN underperformed the US Medical Equipment industry which returned 20.3% over the past year.
Return vs Market: SNN underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| SNN volatility | |
|---|---|
| SNN Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SNN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SNN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1856 | 18,000 | Deepak Nath | www.smith-nephew.com |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Smith & Nephew plc Fundamentals Summary
| SNN fundamental statistics | |
|---|---|
| Market cap | US$10.72b |
| Earnings (TTM) | US$305.00m |
| Revenue (TTM) | US$5.64b |
35.1x
P/E Ratio1.9x
P/S RatioIs SNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNN income statement (TTM) | |
|---|---|
| Revenue | US$5.64b |
| Cost of Revenue | US$1.67b |
| Gross Profit | US$3.97b |
| Other Expenses | US$3.66b |
| Earnings | US$305.00m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 70.33% |
| Net Profit Margin | 5.41% |
| Debt/Equity Ratio | 66.7% |
How did SNN perform over the long term?
See historical performance and comparison